NEW YORK ─ Amoy Diagnostics of Xiamen, China, said on Thursday that it has inked an agreement with Shanghai-based Haihe Pharmaceutical to codevelop a companion diagnostic test for the Japanese market.
The CDx, based on AmoyDx's PCR platform, is being developed for use with Haihe's MET kinase inhibitor Glumetinib (SCC244), which targets c-MET exon14 skipping alterations in patients with non-small cell lung cancer.